DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20174392

Benefits of maternal vaccination to prevent pertussis in infants

Alvaro Monterrosa-Castro, Andrea Ramirez-García, Teresa Beltrán-Barrios

Abstract


Pertussis, also called whooping cough, is an infectious and preventable pathology that generates important child morbidity and mortality worldwide. There are different biological preparations for its use in infants, while for adolescents and adults is Tdap, (acellular vaccine of purified extracts of Bordetella pertussis (BP), combined with tetanus and diphtheria toxoid) that has been proposed as maternal vaccination (MV). The objective was to identify the benefits of MV in the prevention of childhood pertussis, a review was made in PubMed, Science Direct, EBSCOhosT, OvidSP and Embase databases (years 2008-2016) and an electronic alert system (January-April 2017). 1083 titles were identified and 44 articles were selected. After the MV (administered between 27 and 36 weeks of gestation) the passage of IgG-BP to the fetus is sufficient to generate adequate infant protection, generating two benefits: reducing infant morbidity (number of cases and hospital admissions) and decreasing mortality by pertussis. The MV offers 93% of effectiveness [95%CI: 81-97] and OR: 0.09 [95%CI: 0,03-0,25]. The MV is more favorable in each pregnancy than cocoon strategy, vaccination before pregnancy, before 26 weeks of gestation or in the postpartum. The use of MV is a safe and cost-effectiveness tool to prevent childhood pertussis.


Keywords


Infant mortality, Obligatory vaccination, Pertussis, Prenatal Care, Vaccination

Full Text:

PDF

References


Varan AK, Esteves-Jaramillo A, Richardson V, Esparza-Aguilar M, Cervantes-Powell P, Omer SB. Intention to accept Bordetella pertussis booster vaccine during pregnancy in Mexico City. Vaccine. 2014;32:785-92.

Sukumaran L, McCarthy NL, Kharbanda EO, McNeil MM, Naleway AL, Klein NP, et al. Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. JAMA. 2015;314(15):1581-7.

Swamy GK, Wheeler SM. Neonatal pertussis, cocooning and maternal immunization. Expert Rev Vaccines. 2014;13(9):1107-14.

Talbot EA, Brown KH, Kirkland KB, Baughman AL, A Halperin SA, Broder KR. The safety of immunizing with tetanus–diphtheria–acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine. 2010;28(50):8001-7.

Centers for Disease Control and Prevention (CDC). Pertussis (Whooping Cough). Disponible en: https://www.cdc.gov/pertussis/index.html. Accessed on 3 July 2017.

Heininger U, Riffelmann M, Bär G, Rudin C, von König C-HW. The protective role of maternally derived antibodies against Bordetella pertussis in young infants. Pediatr Infect Dis J. 2013;32(6):695-8.

Rath BA, Register KB, Wall J, Sokol DM, Van Dyke RB. Persistent Bordetella bronchiseptica pneumonia in an immunocompetent infant and genetic comparison of clinical isolates with kennel cough vaccine strains. Clin Infect Dis. 2008;46(6):905-8.

WHO. Pertussis vaccines: WHO position paper. August 2015. Disponible en: http://apps.who.int/iris/ bitstream/10665/242413/1/WER9035_433-458.PDF Accessed on 3 July 2017.

Lugnér AK, Van Der Maas N, Van Boven M, Mooi FR, de Melker HE. Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine. 2013;31(46):5392-7.

Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway AL, et al. Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine. 2016;34(7):968-73.

Westra T, Vries R, Tamminga J, Sauboin C, Postma M. Cost-Effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Therapeutics. 2010;32(8):1479-95.

Van Hoek AJ, Campbell H, Amirthalingam G, Andrews N, Miller E. Cost-effectiveness and programmatic benefits of maternal vaccination against pertussis in England. J Infection. 2016;73(1):28-37.

Terranella A, Asay GR, Messonnier ML, Clark TA, Liang JL. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics. 2013;131(6):1748-56.

Vilajeliu A. Goncé A, López M, Costa J, Rocamora L, Ríos J, et al. Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn. Vaccine. 2015;33(8):1056-62.

National Institute of Health, Ministry of Health of Colombia. Protocol of Surveillance in Public Health. Whooping cough. PRO-R02.013. Versión-03. 11-junio-2014. Available at: http://www.ipsunipamplona. com/es/images/sampledata/sivigila_2015/protocolos_epidemiologicos/PRO%20Tos%20ferina.pdf Accessed on 3 June 2017.

Department of Epidemiology. Ministry of Health. Chile's goverment. Whooping cough or whooping cough (CIE-10:A37.0-A37.9). Epidemiological situation, January-September 2015. Quarterly Epidemiological Bulletin. 2015;111(4).

Cohen R, Gaudelus J, Denis F, Stahl P, Chevaillier O, Pujol P, et al. Pertussis vaccination coverage among French parents of infants after 10 years of cocoon strategy. Med Infect Dis. 2016;46(4):188-93.

Pan American Health Organization. File disease: Tosferina (pertussis). Epidemiological alert. 16 de noviembre 2012. Available at http://www2.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=19325〈=es Accessed on 3 June 2017.

Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway A, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014;312(18):1897-904.

Organización Mundial de la Salud. Estadísticas Sanitarias Mundiales. 2014. Disponible en: http://apps.who.int/iris/bitstream/10665/131953/1/9789240692695_spa.pdf Accessed on 3 June 2017.

Baxter R, Bartlett J, Fireman B, Lewis E, Klein N. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics. 2017;139(5):e20164091:1-8.

Meregaglia M, Ferrara L, Melegar A, Demichel V. Parent “cocoon” immunization to prevent pertussis-related hospitalization in infants: The case of Piemonte in Italy. Vaccine. 2013;31(8):1135-7.

Ministerio de Salud y Protección Social de Colombia. Lineamiento estratégico para la introducción de la vacuna TdaP (Tétanos - Difteria – Tosferina acelular) en el esquema del programa ampliado de inmunizaciones [PAI] para mujeres gestantes de las cohortes 2013 y 2014. Disponible en: https://www.minsalud.gov.co/Documentos% 20y%20Publicaciones/lineamiento%20Estrat%C3%A9gico%20para%20la%20Introducci%C3%B3n%20de%20la%20Vacuna%20TdaP.pdf Accessed on 3 June 2017.

Maertens K, Caboré RN, Huygen K, Hens N, Van Damme P, Leuridan E. Pertussis vaccination during pregnancy in Belgium: results of a prospective controlled cohort study. Vaccine. 2016;34(1):142-50.

Omer SB. Maternal immunization. N Engl J Med. 2017;376:1256-67.

Abu Raya B, Bamberger E, Almog M, Peri R, Srugo I, Kessel A. Immunization of pregnant women against pertussis: The effect of timing on antibody avidity. Vaccine. 2015;33(16):1948-52.

Munoz FM, Bond NH, Maccato M, Pinell P, Hammill Ha, Swamy GK, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA. 2014;311(17)):1760-9.

Donaldson B, Jain P, Holder BS, Lindsay B, Regan L, Kampmann B. What determines uptake of pertussis vaccine in pregnancy? A cross sectional survey in an ethnically diverse population of pregnant women in London. Vaccine. 2015;33(43):5822-8.

Healy MC, Rench MA, Baker CJ. Importance of Timing of Maternal Combined Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Immunization and Protection of Young Infants. Clin Infect Dis. 2013;56(4):539-44.

Hoang HT, Leuridan E, Maertens K, Nguyenb TD, Hens N, Vu NH, et al. Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy. Vaccine. 2016;34(1):151-9.

Healy CM, Rench MA, Wootton SH, Castagnini LA. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis. 2015;34(1):22-6.

Matlow J, Pupeo A, Bozzo P, Koren G. Tdap vaccination during pregnancy to reduce pertussis infection in young infants. Can Fam Physician. 2013;59:497-8.

Abu Raya B, Srugo I, Kessel A, Peterman M, Bader D, Gonen R, et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study. Vaccine. 2014;32(44):5787-93.

Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al. Effectiveness of pertussis maternal vaccination in England: an observational study. Lancet. 2014;384(9953):1521-8.

Carcione D, Regan AK, Tracey L, Mak DB, Gibbs R, Dowse GK, et al. The impact of parental postpartum pertussis vaccination on infection in infants: a population-based study of cocooning in Western Australia. Vaccine. 2015;33(42):5654-61.

Dabrera G, Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. Clin Infec Dis. 2015;60(3):333-7.

Vizzotti C, Juarez MV, Bergel E, Romanin V, Califano G, Sagradini S, et al. Impact of a maternal immunization program against pertussis in a developing country. Vaccine. 2016;34(50):6223-8.

Castagnini LA, Healy M, Rench MA, Wootton SH, Muñoz FM, Baker CJ. Impact of maternal postpartum tetanus diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis. 2012;54(1):78-84.

Libster R, Edwards KM. How Can We Best Prevent Pertussis in Infants? Clin Infec Dis. 2012;54(1):85-7.

Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus–diphtheria–pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol. 2011;204(4):334:1-5.

Skowronski DM, Janjua NZ, Tsafack EP, Ouakki M, Hoang L, De Serres G. The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clin Infect Dis. 2012;54(3):318-27.

Fernández-Cano M, Armadans-Gil L, Campins-Martín M. Cost–benefit of the introduction of new strategies for vaccination against pertussis in Spain: cocooning and pregnant vaccination strategies. Vaccine. 2015;33(19):2213-20.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women. Advisory Committee on Immunization Practices (ACIP), 2012. MMWR. 2013;62(7):131-5.

Berenson AB, Hirth JM, Rahman M, Laz TH, Rupp RE, Sarpong KO. Maternal and infant outcomes among women vaccinated against pertussis during pregnancy. Hum Vaccin Immunother. 2016;12(8):1965-71.

Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vazquez-Benitez G, McNeil MM, et al. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. Obstet Gynecol. 2015;126(5):1069-74.

Morgan JL, Baggari SR, McIntire DD, Sheffield JS. Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. Obstet Gynecol. 2015;125(6):1433-8.

Zheteyeva YA, Moro PL, Tepper NK, Rasmussen SA, Barash FE, Revsina NV, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol. 2012;207(1):1-7.

Sartori AM, de Soárez PC, Fernandes EG, Gryninger LC, Viscondi JY, Novaes HM. Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil. Vaccine. 2016;34(13):1531-9.

Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months. Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60(41):1424-6.

Winter K, Nickell S, Powell M, Harriman K. Effectiveness of prenatal versus postpartum tetanus, diphtheria, and acellular pertussis vaccination in preventing infant pertussis. Clin Infect Dis. 2017;64(1):3-8.

Forsyth K, Plotkin S, Tan T, Wirsing von König CH. Strategies to decrease pertussis transmission to infants. Pediatrics. 2015;135:1475-82.

Healy CM, Rench MA, Montesinos DP, Ng N, Swaim LS. Knowledge and attitiudes of pregnant women and their providers towards recommendations for immunization during pregnancy. Vaccine. 2015;33(41):5445-51.

Strategic Advisory Group of Experts (SAGE) on immunization. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009 – Conclusions and recommendations. Biologicals. 2010;38:170-7.